Published in final edited form as:

Bioorg Med Chem. 2009 May 1; 17(9): 3308–3316. doi:10.1016/j.bmc.2009.03.046.

Design and Synthesis of a Novel Tyrosine Kinase Inhibitor Template

P. Jake Slavish^a, Qin Jiang^b, Xiaoli Cui^b, Stephan W. Morris^{b,c}, and Thomas R. Webb^{a,*}

^a Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678

^b Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678

^c Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678

Abstract

We report the design and synthesis of an insulin receptor kinase family-targeted inhibitor template using the inhibitor conformation observed in an IGF1R/inhibitor co-crystal complex by application of a novel molecular design approach that we have recently published. The synthesis of the template involves a one pot Opatz cyclization reaction that provides a versatile indole ester in good yields. We also developed the required chemistry to elaborate this template with additional substituents and have used this chemistry to prepare some initial compounds that show selective inhibition of anaplastic lymphoma kinase (ALK).

Keywords

Anaplastic lymphoma kinase; ALK; *de novo* ligand design; kinase template synthesis; insulin receptor kinase family; inhibitor design

Introduction

Often the discovery of new lead structures for drug discovery projects starts from active molecules (hits) that are found from the screening of compound libraries using *in vitro* assays or cell-based high-throughput screening. However, in some cases, it is possible to design 'hits' if sufficient information is available. We have recently published a detailed report on a novel and general method for *de novo* protein ligand design that uses pharmacophore-based geometry queries, or other similar information, to search virtual hydrocarbon databases for rigid frameworks that match the *geometry* of the query.¹ These new frameworks can then be used as starting points in the design of new structures that contain the constrained pharmacophore interaction features.¹ One of the general applications of this design method makes use of a pharmacophore query derived from the bound conformation of an inhibitor, as observed in a

*E-mail: thomas.webb@stjude.org.

Supplementary data: All additional experimental details including methods for the kinase inhibition determination, NMR spectra and HPLC purity data are included in the Supplementary Data.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

protein-inhibitor crystal structure.² A specific application of this approach to the inactive form of an oncogenic tyrosine kinase has previously been presented.³ The development of new inhibitors of certain tyrosine kinases in the insulin receptor superfamily is of great interest since compounds that demonstrate an appropriate inhibition selectivity profile show promise as potential drugs for the treatment of human malignancies caused by specific gain-of-function oncogenic kinase mutations.^{4–8} We report here details of the design of a novel kinase inhibitor template as well as the synthesis of a partially elaborated template and initial activity data.

Using the general published approach,¹ we searched a virtual framework library (VFL) using the pharmacophore shown in Figure 1, which was derived from a co-crystal structure of a ligand bound to the non-activated IGF1R kinase domain.² We utilized a pharmacophore with all of the interaction features converted to hydrophobic for the initial search of the VFL, as previously described.^{1–3} This search yielded a large number of polycyclic framework hits that were then subjected to selection based on synthetic and medicinal chemistry expertise. This led to the selection of framework hit **1a** (see Figure 2) since it was a close match to four of the five features and also had a synthetically attractive framework. We then targeted the synthesis of compounds containing this core template as a starting point for the design of selective inhibitors of relevant oncogenic tyrosine kinases in the insulin receptor superfamily by the stabilization of the inactive form of their kinase domains.

Results

As outlined in our retrosynthetic plan (Figure 3) the synthesis of tetracyclic pyridone **1** can start with compounds such as ester **4/5**, which can be prepared from commercially available 2-iodoaniline (or 5-chloro-2-iodoaniline, Scheme 1) by iodo-vinyl exchange using phosphine-free, thermal Heck conditions⁹ in 86/92% yield. Treatment of the resulting ester **4/5** with aldehyde **6** (made from the commercially available ester)¹⁰ using modified Opatz conditions^{11, 12} provided the indole ester **7/8** in 73/68% yield. Deprotection of the *t*-butyl ester, followed by amide coupling gave indole amide **9/10** in 80/74% overall yield. We initially investigated the direct base-catalyzed cyclization to form the seven-membered lactam^{13, 14} using **9/10** as a substrate, but the yield of the desired cyclized product was quite low. However, we found that amide reduction followed by base treatment yielded the tetracyclic pyridines **11a/12a** and **11b/12b** in 34% and 24/21% yields, respectively, over two steps. Acid-promoted cyclization of the amine¹⁵ failed to provide the desired tetracyclic compound.

Though the cyclization was not regioselective, these compounds were readily separable and we viewed the diversity of these structures as an opportunity for our envisioned kinase inhibitory structure-activity studies on final compounds derived from both of these two templates.

Direct conversion of chlorides **11a/12a** and **11b/12b** to the corresponding pyridones, using the published acidic conditions (HOAc, 16 HCl¹⁷) and basic conditions (KOH/DMSO)¹⁸ failed to provide the desired products. For this reason, we chose to convert the chloro intermediates to the corresponding ethers, which could serve as a precursor to the pyridone (see Scheme 2). While sodium methoxide (in methanol or toluene)¹⁹ under reflux conditions and DMAP yielded only partial chloro to methoxy conversion, we found that barium hydroxide (octahydrate) in the presence of excess DMAP in refluxing methanol provided complete conversion to ethers **13a/14a** and **13b** in 54/51% and 54% yield (Scheme 2). Though barium hydroxide is used quite often as the base for Suzuki couplings^{20, 21} and as an ester saponification reagent,^{22, 23} the aforementioned exchange catalyzed by barium hydroxide appears rather new. Ether **13a** could readily be converted to pyridone **1**²⁴ in a modest yield of 63% after recrystallization. Structural confirmation of pyridone **1** was achieved via X-ray crystal determination (Figure 5). Using Buchwald conditions, ether **14a** was converted to its

amino analogue **15**. Using a synthetic approach similar to Scheme 1 we synthesized various aryl analogues (Scheme 3).

Discussion

With this initial set of compounds in hand, we investigated their inhibitory effects on a set of kinases using *in vitro* enzymatic assays, performed as previously reported.⁵ As can be seen (TABLE 1), depending on the position of the regioisomer and the substituents, we were able to identify initial compounds with the desirable selectivity for the oncogenic human anaplastic lymphoma kinase (ALK).^{5,25} For example, compounds such as **24b**, **25a** and **26a** showed selectivity for ALK as compared to the highly homologous (and clinically relevant due to the possibility of iatrogenic diabetes with its inhibition) human insulin receptor kinase (IRK), exhibiting IC₅₀s in the single-digit micromolar range for ALK and greater than the highest compound concentration tested (40 μ M) for the IRK. We have previously observed that this degree of selectivity at the hit stage indicates that these 'hits' may be converted into more potent and selective compounds. The relative potency of regioisomers such as **25b** versus **25a** was unexpected and could be due to difference in the kinase domain structure of ALK versus IGF1R, X-ray crystal structure of ALK remain unpublished at this time. The observed potencies are 'hit-like' and demonstrates the utility of our framework design method to identify compounds that are suitable starting points for further optimization into more potent selective inhibitors for additional iterations of medicinal chemistry.

Conclusion

We report the details on the specific application of our recently published 'framework' design¹ of a new kinase inhibitor template and the synthesis of the subject of this design, a novel tetracyclic pyridone tyrosine kinase inhibitor template, which was accomplished in 8 steps.²⁶ This synthesis involves a one pot di-*ortho*-substituted aldehyde condensation, followed by the cyanide-catalyzed cyclization, which gave the key indole intermediate in >70% yield. In addition, we report the first example of barium hydroxide-catalyzed chloro-to-methoxy pyridine conversion. Finally, we present initial structure-activity data showing that representative examples of compounds based on these templates demonstrate activity and initial selectivity for anaplastic lymphoma kinase (ALK), thus indicating that they are suitable starting points for the development of more active 'lead-like' inhibitors through the usual process of 'hit-to-lead' chemistry. A future avenue of research will be the exploration of these templates for the discovery of new therapeutic leads against oncogenic tyrosine kinases in the insulin receptor superfamily such as ALK.^{5, 25}

EXPERIMENTAL

General Remarks

All reactions were performed under an atmosphere of nitrogen. Flash chromatography purifications employed silica gel 60 from EMD Chemicals (particle size: 0.040–0.063 mm, 230–400 mesh ASTM). Thin layer chromatography was performed on silica gel with UV-254 indicator (250 micron thickness). All TLC visualizations were conducted with UV light. Nuclear magnetic resonance experiments were conducted using a 400 MHz II instrument (Bruker Avance II). Microwave reactions were conducted using a Biotage Initiator 60 (N = 100–300W, H = 50–150W, VH = 40–90W). HPLC analyses were accomplished using an UPLC/UV/ELSD/SQD (Single Quadrapole Detector) with stationary phase: BEH C18, 1.7 μ m, solvents: A: 0.1% formic acid in water, B: 0.1% formic acid in acetonitrile, detector types: PDA (210 to 400 nm) and ELSD.

X-ray crystallographic data

Crystallographic data (excluding structure factors) for the structures in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 711726. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, (fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk).

(E)-tert-butyl 3-(2-aminophenyl)acrylate (4)—To a solution of iodoaniline (5.5 g, 25.0 mmol), acrylate (3.8 mL, 26.2 mmol) and sodium bicarbonate (5.3 g, 62.4 mmol) in DMF (8 mL) was added palladium acetate (0.3 g, 1.3 mmol) in one portion. The resulting mixture was heated to 70 °C for 16 h. The mixture was then diluted with EtOAc and filtered through celite. After concentrating under reduced pressure, crude product was purified via column chromatography (EtOAc:Hexanes, 10:90) to provide the ester **4** (4.72 g, 86%) as a yellow solid. mp 76–78 °C. ¹H NMR (CDCl₃) δ 7.75 (d, *J* = 15.8 Hz, 1H), 7.38 (dd, *J* = 7.8, 1.3 Hz, 1H), 7.17 (t, *J* = 7.5, 1.6 Hz, 1H), 6.78 (t, *J* = 7.6, 1.5 Hz, 1H), 6.72 (d, *J* = 8.1 Hz, 1H), 6.32 (d, *J* = 15.8 Hz, 1H), 3.93 (bs, 2H), 1.56 (s, 9H). ¹³C NMR (CDCl₃) δ 166.7, 145.4, 139.1, 128.1, 120.2, 120.1, 118.9, 116.7, 80.5, 28.3. HRMS (ESI) *m/z* Calcd for C₁₃H₁₈NO₂ (M+1)⁺ 220.1338, found 220.1332.

(E)-tert-butyl 3-(2-amino-4-chlorophenyl)acrylate (5) was prepared in a similar manner to conditions for ester **2** to give ester **5** (92%) as a yellow solid. mp 63–65 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, 1H, *J* = 15.8 Hz), 7.20 (d, 1H, *J* = 8.1 Hz), 6.63 (m, 2H), 6.18 (d, *J* = 15.8 Hz, 1H), 1.44 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 166.4, 146.2, 137.9, 136.5, 129.2, 120.7, 119.1, 118.6, 116.1, 100.0, 80.7, 28.3. HRMS (ESI) *m/z* Calcd for C₁₃H₁₆NO₂Cl (M+1)⁺ 253.08695, found 253.08688.

tert-butyl 2-(2-(2,4-dichloro-6-methylpyridin-3-yl)-1H-indol-3-yl)acetate (7)—To a solution of amine **4** (1.4 g, 6.4 mmol) and aldehyde **6** (1.5 g, 7.7 mmol) in EtOH (5 mL) was added HOAc (0.6 mL, 10.2 mmol). After two hrs, the solvent was removed under reduced pressure. The resulting crude imine was treated with potassium cyanide (0.9 g, 14.1 mmol) and additional acetic acid (0.37 mL, 6.4 mmol). The reaction mixture was heated to 70 °C stirred for 22 h. Once deemed complete, the solvent was removed under reduced pressure. Crude product was taken up in EtOAc and washed with sat. aq. NaHCO₃ solution. The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude ester was purified via column chromatography (EtOAc:Hexanes, 20:80) to furnish the indole ester **7** (1.84 g, 73%) as a yellow oil. ¹H NMR (CDCl₃) δ 7.90 (s, 1H), 7.66 (d, *J* = 7.9 Hz, 1H), 7.33 (d, *J* = 8.1 Hz, 1H), 7.24 (s, 1H), 7.19 (m, 3H), 7.12 (t, *J* = 7.5 Hz, 1H), 3.43 (d, *J* = 1.0 Hz, 2H), 2.54 (s, 3H), 1.48 (s, 9H). ¹³C NMR (CDCl₃) δ 170.2, 160.3, 152.4, 147.5, 136.2, 122.8, 127.5, 123.0, 120.1, 119.9, 111.1, 110.1, 80.7, 32.5, 27.9, 24.0. HRMS (ESI) *m/z* Calcd for C₂₀H₂₁N₂O₂Cl₂ (M+1)⁺ 391.0980, found 391.0976.

tert-butyl 2-(6-chloro-2-(2,4-dichloro-6-methylpyridin-3-yl)-1H-indol-3-yl)acetate (8) was prepared in a similar manner to the conditions above for **4** to give **8** (68%) as a off-white solid. mp 72–74 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.21 (s, 1H), 7.79 (d, *J* = 1.8 Hz, 1H), 7.20 (m, 3H), 3.36 (d, *J* = 3.3 Hz, 2H), 2.50 (s, 3H), 1.28 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 169.9, 160.6, 152.3, 147.5, 136.5, 129.0, 128.2, 126.3, 123.2, 121.1, 111.1, 110.3, 80.9, 32.4, 27.9, 24.0. HRMS (ESI) *m/z* Calcd for C₂₀H₂₀N₂O₂Cl₃ (M+1)⁺ 425.0590, found 425.0571.

2-(2-(2,4-dichloro-6-methylpyridin-3-yl)-1H-indol-3-yl)-N-phenethylacetamide (9)—A solution of indole ester **5** (1.7 g, 4.0 mmol) in dichloromethane (3 mL) was treated with trifluoroacetic acid (3.0 mL, 40.0 mmol). The solution stirred at RT for 1 h. The solvent was then removed under reduced pressure. The crude acid was dissolved in DMF, treated with

4-methylmorpholine (1.3 mL, 12.0 mmol) followed by HBTU (2.3 g, 6.0 mmol) and phenethylamine (0.6 mL, 4.8 mmol) in one portion. After 1 h, the mixture was diluted with EtOAc and washed with sat. aq. NaHCO₃ solution, dried with sodium sulfate, filtered and concentrated under reduced pressure. Crude product was purified via column chromatography (EtOAc:Hexanes, 1:1) to yield indole amide **9** (0.50 g, 80%) as an off-white solid. mp 165–167 °C. ¹H NMR (CDCl₃) δ 8.02 (s, 1H), 7.54 (d, *J* = 8.0 Hz, 1H), 7.40 (d, *J* = 8.2 Hz, 1H), 7.29 (t, *J* = 7.5 Hz, 1H), 7.20 - 7.15 (m, 3H), 7.05 - 6.90 (m, 3H), 6.67 (d, *J* = 6.9 Hz, 2H), 5.62 (s, 1H), 3.47 (q, *J* = 17.5 Hz, 2H), 3.39-3.22 (m, 2H), 2.55-2.48 (m, 5H). ¹³C NMR (CDCl₃) δ 170.2, 161.3, 152.5, 147.3, 138.3, 135.9, 128.6, 127.5, 126.2, 123.4, 120.6, 119.1, 111.4, 109.4, 40.3, 35.6, 32.6, 24.0. Anal. Calcd for (C₂₄H₂₁Cl₂N₃O) C, 65.76, H, 4.83, N 9.59. Found: C, 65.22, H, 4.81, N 9.39. HRMS (ESI) *m/z* Calcd for C₂₄H₂₂N₃OCl₂ (M+1)⁺ 438.1140, found 438.1144.

2-(6-chloro-2-(2,4-dichloro-6-methylpyridin-3-yl)-1H-indol-3-yl)-N-

phenethylacetamide (10) was prepared in a similar manner to above conditions for **5** to give amide **10** (74%) as a transparent oil. ¹H NMR (400 MHz, CDCl₃) δ 9.25 (s, 1H), 7.47 - 7.42 (m, 2H), 7.22 (s, 1H), 7.16 (dd, *J* = 8.4, 1.4 Hz, 1H), 7.11 - 7.01 (m, 3H), 6.76 (m, 2H), 5.65 (t, *J* = 5.6 Hz, 1H), 3.53 - 3.27 (m, 4H), 2.78 (s, 5H). ¹³C NMR (100 MHz, CDCl₃) δ 170.2, 161.0, 152.1, 147.2, 138.2, 136.8, 129.4, 128.5, 128.4, 125.8, 123.4, 123.2, 121.3, 120.1, 111.6, 109.1, 40.5, 38.6, 35.4, 32.6, 24.0. HRMS (ESI) *m/z* Calcd for C₂₄H₂₀N₃OCl₃ (M+1)⁺ 472.0750, found 472.0758.

Compounds 11a and 11b—A refluxing mixture of amide **9** (0.6 g, 1.3 mmol) and boron trifluoride dimethyl etherate (0.2 mL, 2.2 mmol) in THF (3 mL) was exposed to 1.0 M borane-THF complex (3.9 mL, 3.9 mmol in THF) for 3 h. After this time, the reaction was cooled to 0 °C and quenched with 4.5 N HCl (3 mL). The mixture was stirred for 1 h and then at RT for 1 h. The mixture was then cooled to 0 °C and basified to pH 13 with solid KOH and extracted with CH₂Cl₂ (10 mL) 3 times. The organic solution was dried (sodium sulfate), filtered and concentrated to afford the amine, which was diluted in DMF (5 mL) and treated triethylamine (0.2 mL, 1.3 mmol). The reaction was heated to 70 °C for 16 h, then quenched via the addition of water (5 mL) at RT. The aqueous layer was extracted with EtOAc (5 mL). The organic layer was dried, filtered and concentrated under reduced pressure. The regioisomers were separated via column chromatography (EtOAc:Hexanes, 9:1 to 4:1) to afford pure 2-chloro pyridine **11a** (0.17 g, 34%) as an off-white solid. mp 165–166 °C. ¹H NMR (CDCl₃) δ 8.95 (s, 1H), 7.41 (d, *J* = 7.8 Hz, 1H), 7.31 (d, *J* = 8.1 Hz, 1H), 7.18 - 7.00 (m, 7H), 6.57 (s, 1H), 3.53 (t, *J* = 7.6 Hz, 2H), 3.46 (t, *J* = 5.6 Hz, 2H), 2.97 (t, *J* = 5.6, 2H), 2.86 (t, *J* = 7.6 Hz, 2H), 2.39 (s, 3H). ¹³C NMR (CDCl₃) δ 161.5, 154.0, 139.8, 139.4, 135.4, 134.7, 127.2, 126.3, 126.0, 122.8, 118.8, 116.7, 115.5, 110.3, 109.2, 53.5, 51.9, 34.7, 27.1, 23.6. HRMS (ESI) *m/z* Calcd for C₂₄H₂₃N₃Cl (M+1)⁺ 388.1581, found 388.1589. 4-chloro pyridine **11b** (0.12 g, 24%) was a yellow solid. Yield: 24%, mp 155–156 °C. ¹H NMR (CDCl₃) δ 8.92 (s, 1H), 7.52 (d, *J* = 7.8 Hz, 1H), 7.37 (d, *J* = 8.1 Hz, 1H), 7.19-7.00 (m, 7H), 6.8 (s, 1H), 3.86 (t, *J* = 7.7 Hz, 2H), 3.57 (t, *J* = 7.5 Hz, 2H), 3.09 (t, *J* = 5.4 Hz, 2H), 3.02 (t, *J* = 7.7 Hz, 2H), 2.45 (s, 3H). ¹³C NMR (CDCl₃) δ 160.6, 154.8, 147.0, 138.8, 135.4, 128.9, 127.2, 126.7, 123.2, 118.5, 116.1, 113.5, 110.6, 109.5, 54.2, 53.9, 34.7, 26.5, 23.9. HRMS (ESI) *m/z* Calcd for C₂₀H₂₁N₂O₂Cl₂ (M+1)⁺ 388.1581, found 388.1563.

Compounds 12a and 12b—These compounds were prepared in a similar manner to the above cyclization from amide **10** to give 2-chloro pyridine **12a** (34%) as an off-white solid. mp 152–154 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.02 (s, 1H), 7.41 (d, *J* = 1.7 Hz, 1H), 7.36 (d, 1H, *J* = 8.4 Hz), 7.18 - 7.05 (m, 6H), 6.66 (s, 1H), 3.63 (t, *J* = 7.4 Hz, 2H), 3.52 (t, *J* = 5.6 Hz, 2H), 3.00 - 2.92 (m, 4H), 2.46 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.5, 155.0, 146.9, 138.7, 135.2, 128.7, 128.5, 128.0, 126.6, 126.3, 120.1, 119.6, 116.0, 113.2, 110.4, 109.5, 54.6, 53.9, 34.4, 26.6, 24.0. HRMS (ESI) *m/z* Calcd for C₂₄H₂₁Cl₂N₃ (M+1)⁺ 422.1191, found

422.1197. 4-chloro pyridine **12b** (21%) was a yellow solid. mp 175–177 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.90 (s, 1H), 7.39 (d, *J* = 8.4 Hz, 1H), 7.35 (d, *J* = 1.6 Hz, 1H), 7.17 - 7.13 (m, 5H), 7.08 (dd, *J* = 8.4, 1.8 Hz, 1H), 6.79 (s, 1H), 3.86 (t, *J* = 7.6 Hz, 2H), 3.53 (t, *J* = 5.5 Hz, 2H), 3.05 - 2.97 (m, 4H), 2.45 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.6, 153.7, 140.2, 139.3, 135.3, 128.9, 128.3, 128.1, 126.5, 120.1, 119.7, 116.7, 115.7, 110.3, 108.7, 53.7, 51.8, 34.7, 26.8, 23.8. HRMS (ESI) *m/z* Calcd for C₂₄H₂₁Cl₂N₃ (M+1)⁺ 422.1191, found 422.1187.

Compound 13a—2-chloro pyridine (0.2 g, 0.4 mmol) and DMAP (0.4 g, 3.6 mmol) was dissolved in methanolic barium hydroxide octahydrate solution (1.2 g, 7.2 mmol Ba (OH)₂·8H₂O, 8 mL methanol). The resulting solution was heated to reflux for 16 h. The methanol was removed under reduced pressure; the crude product was dissolved in EtOAc and washed with water. The organic solution was dried with sodium sulfate, filtered, concentrated and purified via column chromatography (EtOAc:Hexanes, 1:9) to yield ether **13a** (0.07 g, 54%) as a white solid. mp 137–139 °C. ¹H NMR (CDCl₃) δ 10.1 (s, 1H), 7.52 (d, *J* = 7.8 Hz, 1H), 7.40 (d, *J* = 8.1 Hz, 1H), 7.30 - 7.20 (m, 6H), 7.12 (t, *J* = 7.4 Hz, 1H), 6.48 (s, 1H), 4.18 (s, 3H), 3.64 (t, *J* = 7.8 Hz, 2H), 3.50 (t, *J* = 5.4 Hz, 2H), 3.12 (t, *J* = 5.3 Hz, 2H), 3.03 (t, *J* = 7.8 Hz, 2H), 2.43 (s, 3H). ¹³C NMR (CDCl₃) δ 160.9, 158.7, 152.1, 139.3, 134.4, 128.6, 128.2, 126.5, 122.1, 118.1, 113.7, 110.3, 105.9, 100.9, 55.2, 53.8, 52.0, 34.7, 27.8, 24.1. Anal. Calcd for (C₂₅H₂₅N₃O) C, 78.30, H, 6.57, N 10.96. Found: C, 77.95, H, 6.62, N 10.75.

Compound 13b—This compound was prepared in a similar manner to the above methoxy displacement to give ether **13b** (51%) as an off-white solid. mp 80–82 °C. ¹H NMR (CDCl₃) δ 9.75 (s, 1H), 7.51 (d, *J* = 7.8 Hz, 1H), 7.35 (d, *J* = 8.0 Hz, 1H), 7.26 - 7.23 (m, 4H), 7.19 (t, *J* = 8.0 Hz, 2H), 7.10 (t, *J* = 7.0 Hz, 1H), 6.42 (s, 1H), 4.06 (s, 3H), 3.88 (t, *J* = 7.8 Hz, 2H), 3.53 (t, *J* = 5.3 Hz, 2H), 3.12 - 3.08 (m, 4H), 2.48 (s, 3H). ¹³C NMR (CDCl₃) δ 140.6, 134.7, 129.0, 128.4, 128.1, 126.1, 122.1, 118.8, 118.4, 113.4, 110.3, 98.5, 56.0, 54.5, 50.9, 34.9, 29.7, 27.8, 24.8. HRMS (ESI) *m/z* Calcd for C₂₅H₂₆N₃O (M+1)⁺ 384.2076, found 384.2069.

Compound 14a—This compound was prepared in a similar manner to the above methoxy displacement to give ether **14a** (54%) as a clear oil. ¹H NMR (400 MHz, CDCl₃) δ 9.98 (s, 1H), 7.28 (d, *J* = 1.8 Hz, 1H), 7.27 (d, *J* = 8.7 Hz, 1H), 7.18 - 7.07 (m, 7H), 6.96 (dd, *J* = 8.4, 1.8 Hz, 1H), 6.38 (s, 1H), 4.05 (s, 3H), 3.54 (t, *J* = 7.7 Hz, 2H), 3.37 (t, *J* = 5.2 Hz, 2H), 2.95 - 2.86 (m, 4H), 2.32 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 159.1, 156.8, 150.6, 137.4, 132.9, 127.0, 126.8, 125.9, 125.1, 124.7, 117.7, 117.1, 111.9, 108.4, 98.8, 53.4, 52.0, 50.2, 32.8, 25.8, 22.4. HRMS (ESI) *m/z* Calcd for C₂₅H₂₅N₃OCl (M+1)⁺ 418.1686, found 418.1680.

3-Methyl-6-*N*-phenethyl-5,6,7,12-tetrahydroindolo[2,1-*d*]pyrido[4,3-*b*]azepin-1 (2H)-one (1)—To a solution of *O*-methyl pyridine (0.05 g, 140 μmol) in dioxane (0.2 mL) was added 4M HCl (aq.). The mixture was heated to 65 °C for 5 h. Crude product was purified via recrystallization (EtOAc:Hexanes) to afford pyridone **1** (32 mg, 63%) as a tan solid. Yield: 63%, mp 244 °C. ¹H NMR (CDCl₃) δ 12.4 (s, 1H), 9.94 (s, 1H), 7.49 (d, *J* = 7.5 Hz, 1H), 7.41 (d, *J* = 7.5 Hz, 1H), 7.36 - 7.24 (m, 6H), 7.17 (t, *J* = 7.0 Hz, 1H), 7.09 (t, *J* = 7.0 Hz, 1H), 5.85 (s, 1H), 3.65 (t, *J* = 7.6 Hz, 2H), 3.51 (t, *J* = 4.8 Hz, 2H), 3.12 (t, *J* = 4.9 Hz, 2H), 3.08 (t, *J* = 7.6 Hz, 2H), 2.30 (s, 3H). ¹³C NMR (CDCl₃) δ 165.7, 158.1, 140.9, 138.7, 133.7, 132.1, 128.8, 128.0, 126.7, 121.1, 118.5, 117.5, 111.2, 110.6, 100.4, 99.8, 55.4, 51.3, 34.8, 29.7, 26.9, 19.1.

Compound 15—A mixture of **14a** (0.08 g, 0.2 mmol), dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (X-Phos®, 6 mg, 0.01 mmol), and Pd₂(dba)₃ (16 mg, 0.02 mmol) was treated with a solution of *N*-methyl piperazine (0.03 mL, 0.2 mmol) in THF (1 mL). This solution was treated with LiHMDS (0.6 mL, 1M in THF) in one portion. The reaction was heated to 70 °C in a sealed tube overnight. The reaction mixture was dissolved in EtOAc, washed with sat. aq. NaHCO₃ solution, dried over magnesium sulfate, filtered and concentrated

under reduced pressure. Crude product was purified via reverse phase HPLC. Ether **15** (11 mg, 10%) was a tan oil. ^1H NMR (400 MHz, CDCl_3) δ 10.4 (s, 1H), 8.25 (s, 1H), 7.30 – 7.25 (m, 6H), 6.96 (d, J = 1.9 Hz, 1H), 6.75 (dd, J = 8.6, 2.0 Hz, 1H), 4.05 (s, 3H), 3.57 (t, J = 7.8 Hz, 4H), 3.44 (t, J = 5.2 Hz, 4H), 3.12 (t, J = 4.8 Hz, 4H), 3.00 – 2.92 (m, 5H), 2.32 (s, 3H), 2.24 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 163.6, 160.2, 158.1, 150.8, 147.5, 139.4, 135.6, 128.8, 127.0, 126.1, 121.8, 117.9, 112.9, 110.9, 105.4, 100.5, 97.5, 54.8, 54.3, 53.3, 51.5, 50.0, 45.7, 33.7, 27.2, 23.8. HRMS (ESI) m/z Calcd for $\text{C}_{30}\text{H}_{35}\text{N}_5\text{O}$ ($\text{M}+1$) $^+$ 482.2920, found 482.2912.

(E)-tert-butyl 3-(2-amino-4-bromophenyl)acrylate (17) was prepared in a similar manner to conditions for **2** to give ester **17** (92%) as yellow solid. mp 63–65 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.62 (d, J = 15.8 Hz, 1H), 7.48 (d, J = 2.3 Hz, 1H), 7.23 (dd, J = 8.5, 2.2 Hz, 1H), 6.59 (d, J = 8.5 Hz, 1H), 6.29 (d, J = 15.7 Hz, 1H), 3.96 (s, 2H), 1.55 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.2, 155.3, 144.3, 137.5, 133.4, 130.3, 121.9, 121.5, 118.2, 110.6, 80.8, 28.2. HRMS (ESI) m/z Calcd for $\text{C}_{13}\text{H}_{17}\text{NO}_2\text{Br}$ ($\text{M}+1$) $^+$ 298.0443, found 298.0442.

tert-butyl 2-(5-bromo-2-(2-chloro-4-iodopyridin-3-yl)-1H-indol-3-yl)acetate (18) was prepared in a similar manner to the conditions above for **4** to give indole ester **18** (66%) as a yellow solid. mp 181–184 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.05 (s, 1H), 8.00 (d, J = 5.2 Hz, 1H), 7.83 (s, 1H), 7.79 (d, J = 5.2 Hz, 1H), 7.28 (dd, J = 8.6, 1.8 Hz, 1H), 7.24 – 7.18 (m, 2H), 3.36 (d, J = 4.6 Hz, 2H), 1.31 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.6, 151.7, 149.9, 134.6, 134.0, 133.2, 133.2, 129.4, 126.1, 123.1, 114.8, 113.5, 112.8, 108.8, 81.2, 32.5, 28.1. HRMS (ESI) m/z Calcd for $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_2\text{ClBrI}$ ($\text{M}+1$) $^+$ 546.9285, found 546.9272.

2-(5-bromo-2-(2-chloro-4-iodopyridin-3-yl)-1H-indol-3-yl)-N-((S)-1-phenylethyl)acetamide (19) was prepared in a similar manner to above conditions for **5** to give amide **19** (68%) as a tan oil. ^1H NMR (400 MHz, CDCl_3) δ 8.50 (d, J = 9.9 Hz, 1H), 8.03 (dd, J = 5.2, 2.2 Hz, 1H), 7.75 (dd, J = 6.2, 5.4 Hz, 1H), 7.68 (dd, J = 8.8, 1.8 Hz, 1H), 7.33 (dt, J = 8.6, 1.9 Hz, 1H), 7.24 (dd, J = 10.0, 1.2 Hz, 1H), 7.20 – 7.10 (m, 4H), 7.01 (m, 2H), 5.84 (d, J = 8.0 Hz, 1H), 4.99 (qn, J = 7.2 Hz, 1H), 3.46 (dd, J = 17.5, 5.5 Hz, 1H), 3.36 (dd, J = 17.5, 4.5 Hz, 1H), 1.25 (dd, J = 6.9, 5.0 Hz, 3H). ^{13}C NMR (CDCl_3) δ 168.9, 151.4, 151.4, 150.4, 142.9, 142.8, 135.0, 133.3, 132.7, 127.3, 126.1, 122.3, 114.7, 114.0, 113.2, 108.1, 108.0, 49.0, 33.0, 21.8. HRMS (ESI) m/z Calcd for $\text{C}_{23}\text{H}_{19}\text{N}_3\text{OClBrI}$ ($\text{M}+1$) $^+$ 593.9445, found 593.9445.

2-(5-bromo-2-(2-chloro-4-iodopyridin-3-yl)-1H-indol-3-yl)-N-(2-(4-hydroxyphenyl)ethyl)acetamide (20) was prepared in a similar manner to above conditions for **5** to give amide **20** (39%) as a brown oil. ^1H NMR (400 MHz, Acetone) δ 10.64 (s, 1H), 8.20 (bs, 1H), 8.15 (t, J = 4.9 Hz, 1H), 8.04 (t, J = 4.9 Hz, 1H), 7.98 (d, J = 2.4 Hz, 1H), 7.47 (dd, J = 8.6, 4.4 Hz, 1H), 7.36 (m, 1H), 6.83 (m, 2H), 6.63 (m, 3H), 3.46 (t, J = 5.3 Hz, 2H), 3.31 (m, 2H), 2.58 (m, 2H). ^{13}C NMR (101 MHz, Acetone) δ 169.8, 156.7, 151.9, 150.9, 136.3, 136.0, 134.4, 134.3, 130.8, 130.6, 130.5, 126.1, 123.4, 116.1, 115.6, 114.3, 113.2, 109.3, 41.8, 35.7, 33.4. HRMS (ESI) m/z Calcd for $\text{C}_{22}\text{H}_{19}\text{N}_3\text{O}_2\text{ClBrI}$ ($\text{M}+1$) $^+$ 609.9394, found 609.9421.

2-(5-bromo-2-(2-chloro-4-iodopyridin-3-yl)-1H-indol-3-yl)-N-(2,2-diphenylethyl)acetamide (21) was prepared in a similar manner to above conditions for **5** to give amide **21** (94%) as a clear oil. ^1H NMR (400 MHz, CDCl_3) δ 8.34 (s, 1H), 7.95 (d, J = 5.2 Hz, 1H), 7.70 (d, J = 5.2 Hz, 1H), 7.65 (d, J = 1.7 Hz, 1H), 7.37 (dd, J = 8.6, 1.8 Hz, 1H), 7.25 (d, J = 8.6 Hz, 1H), 7.05 – 6.97 (m, 6H), 6.90 – 6.84 (m, 4H), 5.53 (t, J = 5.4 Hz, 1H), 3.82 (t, J = 7.6 Hz, 1H), 3.73 (t, J = 6.7 Hz, 2H), 3.33 (d, J = 5.2 Hz, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.7, 151.4, 150.3, 141.5, 141.4, 135.1, 134.7, 133.0, 132.6, 128.8, 128.6, 128.0, 127.9, 126.8, 126.7, 122.1, 114.7, 114.1, 113.1, 107.8, 50.4, 43.6, 32.7. HRMS (ESI) m/z Calcd for $\text{C}_{29}\text{H}_{23}\text{N}_3\text{OClBrI}$ ($\text{M}+1$) $^+$ 669.9758, found 669.9736.

N-(2-(1H-indol-3-yl)ethyl)-2-(5-bromo-2-(2-chloro-4-iodopyridin-3-yl)-1H-indol-3-yl)acetamide (22) was prepared in a similar manner to above conditions for **5** to give amide **22**

(58%) as a tan solid. mp: 240–242 °C. ^1H NMR (400 MHz, DMSO) δ 11.45 (s, 1H), 10.77 (s, 1H), 8.16 (d, J = 5.2 Hz, 1H), 8.08 (d, J = 5.1 Hz, 1H), 7.94 (d, J = 1.9 Hz, 1H), 7.84 (t, J = 5.7 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.30 (dd, J = 8.6, 2.0 Hz, 1H), 7.06–7.03 (m, 2H), 6.95 (dt, J = 7.5, 1.0 Hz, 1H), 3.30 (m, 5H), 2.72 (t, J = 7.5 Hz, 2H). ^{13}C NMR (101 MHz, DMSO) δ 169.1, 150.3, 149.9, 136.2, 134.9, 134.4, 133.3, 133.2, 129.5, 127.1, 124.2, 122.5, 122.4, 120.9, 118.2, 116.5, 113.3, 111.7, 111.4, 108.1, 31.9, 25.3, HRMS (ESI) m/z Calcd for $\text{C}_{25}\text{H}_{20}\text{N}_4\text{OClBrI}$ ($M+1$) $^+$ 632.9554, found 632.9537.

Compounds 23a/b—These compounds were prepared in a similar manner to the above cyclization from amide **10** except the cyclization step was heated to 170 °C for 1 h using microwave heating (absorbance: normal) to provide **23a** (11%) as a tan solid. mp: 142–146 °C. ^1H NMR (400 MHz, CDCl_3) δ 9.00 (s, 1H), 7.83 (d, J = 5.7 Hz, 1H), 7.51 (s, 1H), 7.29–7.22 (m, 7H), 6.68 (d, J = 5.7 Hz, 1H), 4.96 (q, J = 6.8 Hz, 1H), 3.49 (t, J = 5.5 Hz, 2H), 2.93 (dt, J = 16.7, 5.7 Hz, 1H), 2.72 (dt, J = 16.7, 5.4 Hz, 1H), 1.67 (d, J = 6.9 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 159.8, 147.0, 144.2, 139.6, 132.5, 128.4, 127.8, 127.4, 126.6, 125.9, 125.2, 120.4, 114.7, 113.7, 111.5, 111.1, 110.0, 58.2, 47.6, 26.4, 17.4. HRMS (ESI) m/z Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_3\text{BrCl}$ ($M+1$) $^+$ 452.0529, found 452.0509. Compound **23b** was a tan oil (7%). ^1H NMR (400 MHz, CDCl_3) δ 8.38 (s, 1H), 7.61 (d, J = 4.9 Hz, 1H), 7.47 (d, J = 1.6 Hz, 1H), 7.23 (m, 8H), 5.83 (q, J = 6.9 Hz, 1H), 3.40 (ddd, J = 14.5, 6.5, 4.4 Hz, 1H), 3.18 (ddd, J = 14.3, 8.2, 3.6 Hz, 1H), 2.78 (ddd, J = 16.7, 6.2, 3.7 Hz, 1H), 2.46 (ddd, J = 16.7, 8.2, 4.3 Hz, 1H), 1.61 (d, J = 6.9 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 160.9, 143.0, 140.7, 132.3, 129.0, 128.9, 127.3, 126.9, 126.6, 126.1, 125.0, 120.7, 114.7, 114.4, 111.6, 111.0, 100.9, 54.5, 45.1, 25.9, 15.5, HRMS (ESI) m/z Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_3\text{BrI}$ ($M+1$) $^+$ 543.9885, found 543.9873.

Compounds 24a/b through 26a/b—These compounds were prepared in a similar manner to the above cyclization from amide **10**. Compound **24a** was a tan solid (22%). mp: 217–219 °C. ^1H NMR (400 MHz, Acetone) δ 10.29 (s, 1H), 8.07 (s, 1H), 8.02 (s, 1H), 7.95 (d, J = 5.6 Hz, 1H), 7.66 (d, J = 1.9 Hz, 1H), 7.46 (d, J = 8.6 Hz, 1H), 7.28 (dd, J = 8.6, 1.9 Hz, 1H), 7.07 (d, J = 5.7 Hz, 1H), 7.05 (d, J = 8.4 Hz, 2H), 6.65 (d, J = 8.5 Hz, 2H), 3.65 (m, 4H), 3.12 (t, J = 5.8 Hz, 2H), 2.91 (t, J = 7.7 Hz, 2H). ^{13}C NMR (101 MHz, Acetone) δ 217.5, 214.9, 213.8, 212.7, 212.3, 206.1, 206.1, 161.3, 156.8, 149.1, 146.3, 135.3, 130.7, 130.7, 130.4, 130.2, 126.2, 121.8, 116.4, 116.1, 116.0, 113.8, 112.5, 111.3, 55.6, 55.2, 33.9, 26.8. HRMS (ESI) m/z Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_3\text{OBrCl}$ ($M+1$) $^+$ 468.0478, found 468.0469. Compound **24b** was a brown solid (10%). mp: 208–212 °C. ^1H NMR (400 MHz, DMSO) δ 10.80 (s, 1H), 9.17 (s, 1H), 7.76 (d, J = 4.9 Hz, 1H), 7.73 (d, J = 1.7 Hz, 1H), 7.47 (d, J = 4.9 Hz, 1H), 7.40 (d, J = 8.6 Hz, 1H), 7.30 (dd, J = 8.6, 1.9 Hz, 1H), 7.04 (d, J = 8.4 Hz, 2H), 6.64 (d, J = 8.4 Hz, 2H), 3.72 (t, J = 7.7 Hz, 2H), 3.58 (t, J = 5.4 Hz, 2H), 3.08 (t, J = 5.6 Hz, 2H), 2.85 (t, J = 7.7 Hz, 2H). ^{13}C NMR (101 MHz, DMSO) δ 161.2, 155.5, 144.2, 134.2, 131.5, 129.8, 129.5, 129.4, 127.1, 124.8, 120.8, 117.1, 115.0, 114.1, 113.3, 111.1, 104.9, 52.5, 33.1, 25.5. HRMS (ESI) m/z Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_3\text{OBrI}$ ($M+1$) $^+$ 559.9835, found 559.9857. Compound **25a** was an off-white solid (24%). mp: 112–114 °C. ^1H NMR (400 MHz, Acetone) δ 10.13 (s, 1H), 7.99 (d, J = 5.6 Hz, 1H), 7.33 (d, J = 1.9 Hz, 1H), 7.28 (dd, J = 8.6, 0.4 Hz, 1H), 7.13 (dd, J = 8.6, 1.9 Hz, 1H), 7.00 (dd, J = 7.6, 1.6 Hz, 5H), 6.89 (t, J = 1.8 Hz, 1H), 6.87 (dd, J = 5.8, 1.4 Hz, 3H), 6.84 (t, J = 1.5 Hz, 1H), 6.83 (t, J = 3.0 Hz, 1H), 4.18 (d, J = 8.6, 6.9 Hz, 1H), 4.09 (d, J = 3.9 Hz, 2H), 3.48 (t, J = 5.8 Hz, 2H), 2.57 (d, J = 5.8 Hz, 2H). ^{13}C NMR (101 MHz, Acetone) δ 161.1, 149.2, 146.3, 143.5, 135.3, 130.4, 129.9, 128.9, 128.9, 127.1, 125.9, 121.9, 117.4, 116.6, 113.6, 112.1, 112.1, 58.8, 57.2, 50.6, 26.4, HRMS (ESI) m/z Calcd for $\text{C}_{29}\text{H}_{24}\text{N}_3\text{ClBr}$ ($M+1$) $^+$ 528.0842, found 528.0848. Compound **25b** was a tan oil (3%). ^1H NMR (400 MHz, CDCl_3) δ 8.23 (s, 1H), 7.60 (d, J = 4.9 Hz, 1H), 7.35 (d, J = 1.7 Hz, 1H), 7.29 (d, J = 5.0 Hz, 1H), 7.23 (dd, J = 8.6, 1.8 Hz, 1H), 7.19 (s, 2H), 7.14 (d, J = 8.5 Hz, 1H), 6.96 (m, 10H), 4.25 (m, 3H), 3.37 (t, J = 5.7 Hz, 2H), 2.40 (t, J = 5.7 Hz, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 161.3, 144.1, 142.9, 133.3, 129.8, 129.7, 128.2, 128.1, 128.1, 126.2, 125.9, 121.9, 117.8, 115.9, 112.3, 111.8,

102.3, 57.4, 54.6, 49.9, 25.8. HRMS (ESI) m/z Calcd for $C_{29}H_{24}N_3BrI$ ($M+1$)⁺ 620.0198, found 620.0211. Compound **26a** was a light brown solid (30%). mp: 248–252 °C. ¹H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 10.81 (s, 1H), 7.98 (d, J = 5.6 Hz, 1H), 7.69 (s, 1H), 7.56 (d, J = 7.4 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.25 (d, J = 6.7 Hz, 1H), 7.17 (s, 1H), 7.06 (m, 2H), 6.95 (t, J = 7.1 Hz, 1H), 3.64 (bs, 4H), 3.10 (bs, 2H), 3.06 (bs, 2H). ¹³C NMR (101 MHz, DMSO) δ 160.1, 147.9, 145.4, 136.1, 134.2, 129.2, 128.8, 127.1, 124.8, 122.9, 120.9, 120.6, 118.3, 114.8, 114.5, 113.3, 111.3, 111.3, 111.0, 110.39, 54.2, 53.1, 25.5, 23.1. HRMS (ESI) m/z Calcd for $C_{25}H_{21}N_4ClBr$ ($M+1$)⁺ 491.0638, found 491.0646. Compound **26b** was a tan solid (5%). mp: 208–212 °C. ¹H NMR (400 MHz, DMSO) δ 10.76 (s, 2H), 7.75 (t, J = 4.3 Hz, 1H), 7.69 (bs, 1H), 7.63 (m, 1H), 7.44 (t, J = 4.7, 1H), 7.36 (dd, J = 8.3, 5.3 Hz, 1H), 7.31 (dd, J = 7.9, 4.8 Hz, 1H), 7.25 (m, 1H), 7.11 (bs, 1H), 7.05 (m, 1H), 6.96 (m, 1H), 3.80 (m, 2H), 3.60 (m, 2H), 3.08 (m, 4H). ¹³C NMR (101 MHz, DMSO) δ 161.3, 144.2, 136.2, 134.3, 131.5, 129.4, 127.3, 127.0, 124.8, 122.5, 120.8, 118.5, 118.2, 116.9, 114.1, 113.3, 112.1, 111.3, 111.2, 104.9, 52.3, 51.3, 25.6, 23.6. HRMS (ESI) m/z Calcd for $C_{25}H_{21}N_4BrI$ ($M+1$)⁺ 582.9994, found 583.0003.

Acknowledgments

We would like to thank Antonio DePasquale and Arnold L. Rheingold of the Department of Chemistry at the University of California, San Diego for the X-ray structure determination of **8a**. This work was supported in part by NCI grant CA69129 (S.W.M.) and by the American Lebanese Syrian Associated Charities (ALSAC), St. Jude Children's Research Hospital.

References

1. Webb TR, Venegas RE, Wang J, Deschenes A. J Chem Inf Model 2008;48:882–888. [PubMed: 18335978]
2. Webb, TR.; Wang, J.; McGrath, DE.; Venegas, R. MEDI-218; Abstracts of Papers, 231st American Chemical Society National Meeting; Atlanta, GA, United States. March 26–30, 2006; Washington, DC: American Chemical Society; 2006.
3. Webb, TR.; Li, R.; Zhu, T.; Morris, SW.; Xue, L.; Jiang, Q.; Wang, J.; Cui, X.; McGee, D.; Gantla, V.; Yan, Z.; Pickens, JC.; Zozulya, S.; McGrath, D. MEDI-217; Abstracts of Papers, 231st American Chemical Society National Meeting; Atlanta, GA, United States. March 26–30, 2006; Washington, DC: American Chemical Society; 2006.
4. Kawahara, E.; Miyake, T.; Roesel, J.; (Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.). Application: WO 2006021457 A2, 2006, 83 pp.
5. Li R, Xue L, Zhu T, Jiang Q, Cui X, Yan Z, McGee D, Wang J, Gantla VR, Pickens JC, McGrath D, Chucholowski A, Morris SW, Webb TR. J Med Chem 2006;49:1006–1015. [PubMed: 16451066]
6. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG. Cancer Res 2007;67:4408–4417. [PubMed: 17483355]
7. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Lafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J. Proc Natl Acad Sci U S A 2007;104:19936–19941. [PubMed: 18077425]
8. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. Molecular Cancer Therapeutics 2007;6:3314–3322. [PubMed: 18089725]
9. Huang S, Garbaccio RM, Fraley ME, Steen J, Kreatsoulas C, Hartman G, Stirdivant S, Drakas B, Rickert K, Walsh E, Hamilton K, Buser CA, Hardwick J, Mao X, Abrams M, Beck S, Tao W, Lobell R, Sepp-Lorenzino L, Yan Y, Ikuta M, Murphy JZ, Sardana V, Munshi S, Kuo L, Reilly M, Mahan E. Bioorg Med Chem Lett 2006;16:5907–5912. [PubMed: 16990002]
10. Dyck B, Grigoriadis DE, Gross RS, Guo Z, Marinkovic D, McCarthy JR, Moorjani M, Regan CF, Saunders J, Schwaebe MK, Szabo T, Williams JP, Zhang X, Bozigian H, Chen TK. J Med Chem 2005;48:4100–4110. [PubMed: 15943483]

11. Opatz T, Ferenc D. *Org Lett* 2006;8:4473–4475. [PubMed: 16986928]
12. Opatz T, Ferenc D. *Synthesis* 2008:3941–3944.
13. Sidduri A, Lou JP, Campbell R, Rowan K, Tilley JW. *Tetrahedron Lett* 2001;42:8757–8760.
14. Enders D, Groebner R, Raabe G, Runsink J. *Synthesis* 1996:941–948.
15. Spicer JA, Rewcastle GW, Kaufman MD, Black SL, Plummer MS, Denny WA, Quin J III, Shahripour AB, Barrett SD, Whitehead CE, Milbank JBJ, Ohren JF, Gowan RC, Omer C, Camp HS, Esmaeil N, Moore K, Sebolt-Leopold JS, Pryzbranowski S, Merriman RL, Ortwine DF, Warmus JS, Flamme CM, Pavlovsky AG, Tecle H. *J Med Chem* 2007;50:5090–5102. [PubMed: 17880056]
16. Lavecchia G, Berteina-Raboin S, Guillaumet G. *Tetrahedron Lett* 2004;45:6633–6636.
17. Taylor SD, Mirzaei F, Sharifi A, Bearn SL. *J Org Chem* 2006;71:9420–9430. [PubMed: 17137369]
18. Kagabu S. *Synth Commun* 2006;36:1235–1245.
19. Peters R, Diolez C, Rolland A, Manginot E, Veyrat M. *Heterocycles* 2007;72:255–273.
20. Tucci FC, Zhu Y-F, Guo Z, Gross TD, Connors PJ Jr, Gao Y, Rowbottom MW, Struthers RS, Reinhart GJ, Xie Q, Chen TK, Bozigian H, Bonneville ALK, Fisher A, Jin L, Saunders J, Chen C. *J Med Chem* 2004;47:3483–3486. [PubMed: 15214774]
21. Kano T, Ohyabu Y, Saito S, Yamamoto H. *J Am Chem Soc* 2002;124:5365–5373. [PubMed: 11996577]
22. Anderson MO, Moser J, Sherrill J, Guy RK. *Synlett* 2004:2391–2393.
23. Soengas RG, Anta C, Espada A, Nieto RM, Larrosa M, Rodriguez J, Jimenez C. *Tetrahedron Lett* 2007;48:3021–3024.
24. Velaparthi U, Liu P, Balasubramanian B, Carboni J, Attar R, Gottardis M, Li A, Greer A, Zoeckler M, Wittman MD, Vyas D. *Bioorg Med Chem Lett* 2007;17:3072–3076. [PubMed: 17398093]
25. George RE, Sanda T, Hanna M, Frohling S, Li WL, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. *Nature* 2008;455:975–978. [PubMed: 18923525]
26. As far as the authors are aware, the closest known structures to our template differ significantly from our final structures; see: Kunick C, Lauenroth K, Leost M, Meijer L, Lemcke T. *Bioorg Med Chem Lett* 2004;14:413–416.416 [PubMed: 14698171]

FIGURE 1.

A detailed view of the pharmacophore including measurements in angstroms derived from the bound conformation of a ligand/IGF1R kinase domain co-crystal structure.^{2,3} This pharmacophore was used to search the virtual framework library. The color coding is as follows Green= Aromatic (Aro); Purple= Hydrogen-bond donor (Don); Cyan= Hydrogen-bond acceptor (Acc). The size of each sphere is to scale with the query that was used to search the VFL.¹ The radius dimensions are as follows: Aro= 1.2 angstroms; Don= 0.8 angstroms; Acc= 0.8 angstroms.

FIGURE 2.

The evolution of scaffold **1c** from initial computational hit **1a**. Abbreviations: Hyd= hydrogen bond donor; Acc= hydrogen bond acceptor.

FIGURE 3.
The general retrosynthetic approach to scaffold **1**.

FIGURE 4.

A right-left stereoview of a low energy conformation of **1** (the methyl group on the pyridine is omitted for simplicity) with an overlay of the pharmacophore from Figure 1 generated in MOE. The color coding is as follows Green= Aromatic (Aro); Purple= Hydrogen-bond donor (Don); Cyan= Hydrogen-bond acceptor (Acc). The size of each sphere is to scale with the query that was used to search the VFL.¹ The radius dimensions are as follows: Aro= 1.2 angstroms; Don= 0.8 angstroms; Acc= 0.8 angstroms. Small green dots represent centroids recognized by MOE. See Figure 1 for a detailed view of the pharmacophore.

FIGURE 5.

The single crystal X-ray structure of **1**, which confirms our structural assignment (see supplementary data).

i) *t*-butyl acrylate, cat. Pd(OAc)₂, NaHCO₃, DMF; ii) (a) **6**, HOAc, EtOH; (b) KCN, HOAc, EtOH; iv) trifluoroacetic acid, DCM; v) phenethylamine, HBTU, *N*-methyl morpholine, DMF; vi) 1.0 M borane-THF complex, trifluoroborane-methyl etherate, THF; vii) triethylamine, DMF.

SCHEME 1.

The syntheses of the tetracyclic intermediates **11a/12a** and **11b/12b**.

SCHEME 2.

The synthesis of pyridone or methoxy pyridine inhibitors.

i) *t*-butyl acrylate, cat. Pd(OAc)₂, NaHCO₃, DMF; ii) (a) 2-chloro-4-iodo-nicotinaldehyde, HOAc, EtOH; (b) KCN, HOAc, EtOH; iii) trifluoroacetic acid, DCM; iv) amine, HBTU, *N*-methyl morpholine, DMF; v) 1.0 M borane-THF complex, trifluoroborane-methyl etherate, THF; vi) triethylamine, DMF.

SCHEME 3.
Synthesis of aryl analogues

Biochemical evaluation of pyridone **1** and analogs (using the *in vitro* enzymatic kinase assay previously described in the Supplementary Data).⁵

TABLE 1

ID	ALK	IRK	IGF1R	JAK2	MET
11a	21.3	30.5	24.7	33.5	26.1
11b	11.8	19.8	12.6	>40	12.4
13a	>40	>40	>40	>40	>40
13b	>40	>40	>40	>40	>40
1	18.0	15.6	11.8	16.9	19.7
15	5.1	3.5	4.5	5.1	5.5
23b	8.3	>40	ND [†]	ND	>40
23a	5.8	11.9	ND	ND	12.9
24b	6.2	11.1	ND	ND	9.7
24a	7.1	>40	ND	ND	12.5
25b	5	>40	ND	ND	8.6
25a	>40	>40	ND	ND	>40
26a	9.3	>40	ND	ND	>40

* All IC₅₀ values (μM) are averages from triplicate assays.

[†] Not determined.